



A Valeant Company

30 January 2017

Committee Secretary  
Senate Standing Committees on Community Affairs  
PO Box 6100  
Parliament House  
CANBERRA ACT 2600

By email: [community.affairs.sen@aph.gov.au](mailto:community.affairs.sen@aph.gov.au)

Dear Secretary

**SUBMISSION TO THE COMMITTEE INQUIRY INTO THE PROSTHESES LIST (PL) FRAMEWORK**

On behalf of iNova Pharmaceuticals, a Valeant Company, I am writing in support of the Medical Technology Association of Australia (MTAA) submission to the Senate Community Affairs References Committee.

iNova Pharmaceuticals in Australia supplies a range of Intraocular Lenses (IOLs) that are funded in part via the Prosthesis List.

iNova Pharmaceuticals understands and is supportive of the reform process into private health insurance arrangements the Government has committed to and is aware that further reform of the Prosthesis List is a key part of the Government objectives.

The claims made by private health insurers there are up to \$800m per year in savings to be made from the Prosthesis List are not supported by correct evidence. Also, if this level of value containment were to be implemented through this review process it would have devastating consequences for patients and the healthcare sector.

The medical device industry is innovative, employs thousands of people and is a major export earner.

Additionally, at a time when the Government has committed to an innovation agenda it is important that an innovative industry like the medical device industry has certainty around Government policy. An accessible, robust, and efficient Prosthesis List is a key component for ensuring this occurs.

The Prosthesis List is about ensuring patients with private health insurance have access to best medical technology supported by their medical professional free of external interference.

iNova Pharmaceuticals wants this to continue and therefore fully supports the MTAA Senate submission.

The mandated 10% cut in the rebate level for IOLs effective in February 2017 has caused an immediate negative and confused impact with patients, customers and within the company.

Yours sincerely

Mark Glover  
**MANAGING DIRECTOR –  
AUSTRALIA & NEW ZEALAND**